Evolus (EOLS)
(Delayed Data from NSDQ)
$12.86 USD
-0.15 (-1.15%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $12.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Evolus, Inc. [EOLS]
Reports for Purchase
Showing records 41 - 51 ( 51 total )
Company: Evolus, Inc.
Industry: Medical - Products
Jeuveau Shows That It''s More than Just a Hashtag; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Takeaways From Our Coverage at the Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Evolus and Revance Stand to Gain From Likely Disruption Caused by AbbVie Acquiring Allergan
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Company: Evolus, Inc.
Industry: Medical - Products
Evolus, Inc. and Revance Therapeutics: BoNT-A Market Update After the American Academy of Dermatology Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Evolus, Inc.
Industry: Medical - Products
Slides Reviewing Initiations on Dermatology and Endocrinology
Provider: H.C. Wainwright & Co., Inc.
Company: Evolus, Inc.
Industry: Medical - Products
Cordially invites you to a Coverage Launch Teach-In
Provider: H.C. Wainwright & Co., Inc.
Company: Evolus, Inc.
Industry: Medical - Products
Launching Coverage
Provider: H.C. Wainwright & Co., Inc.
Company: Evolus, Inc.
Industry: Medical - Products
A Fresh Face in Toxins: Initiate at Buy With $37 Price Target
Provider: H.C. Wainwright & Co., Inc.